Safety · 2026-07-03
Virginia Poison Centers Report 12-Fold Rise in Kratom Hospitalizations as State Bans Synthetic 7-OH
Source: WDBJ7 (CBS Virginia)
Why it matters
Poison center data documents a dramatic 12-fold surge in serious kratom-related hospitalizations over a decade, and Virginia has now enacted laws restricting high-concentration 7-OH — a model other states may follow as federal scheduling proceeds.
The big picture
State-level 7-OH regulations have been accelerating as emergency departments and poison centers document escalating caseloads tied to synthetic and concentrated kratom derivatives. Virginia's experience — and its physician-backed legislative response — now feeds into the broader federal DEA scheduling process. Toxicologists emphasize that 7-OH's opioid-like potency makes it fundamentally different from standard botanical kratom.
Key findings
- Blue Ridge Poison Center (UVA) recorded 43 kratom-linked hospitalizations in 2015; by 2025 that number reached 538 — a 12-fold increase over a decade
- Virginia Poison Center director describes 7-OH as '5 to 15 times more potent than morphine'
- Virginia's new law (effective July 1, 2026) bans sale of kratom and 7-OH products above specified thresholds and requires warning labels stating kratom may cause dependence and opioid-like withdrawal
- One documented case involved a patient who became comatose on life support after a single high-concentration 7-OH dose interacted with other medications
- Recovery advocates note that 7-OH's retail availability in gas stations and convenience stores made it easy to access without understanding its potency
What they say
"I haven't found another poison center director who feels it's appropriate to have this out on the shelves," said Dr. John Downs, director of the Virginia Poison Center at Virginia Commonwealth University. "I think it's time for action to restrict its ability to be purchased."
Bottom line
Kratom-related hospitalizations in Virginia surged 12-fold in a decade, and the state's new warning-label and ban law marks a significant regulatory turning point that mirrors the federal DEA scheduling action underway.